Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa

项目 2：马拉维和南非当地标准护理治疗下 HIV 相关卡波西肉瘤进展的临床和分子决定因素

• 批准号: 10434864
• 负责人: Dirk P Dittmer
• 金额: $ 18.45万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-13 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10434864
• 关键词: AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; AIDS with Kaposi' s sarcoma; Adopted; Africa; Africa South of the Sahara; Area; Biological; Biopsy; Bleomycin; Blood; Caring; Cells; Clinical; Clinical Markers; Clinical Trials; Cohort Studies; Collaborations; Collection; Country; Data Set; Detection; Disease; Disease Marker; Doxorubicin Hydrochloride Liposome; Eligibility Determination; Enrollment; Europe; Funding; Gene Expression Profile; Gene Expression Profiling; Genetic Transcription; Genome; Genomics; Goals; HIV; Hospitals; Human; Human Herpesvirus 8; IL6 gene; Incidence; Institutional Review Boards; Interleukin-10; Iris; Joints; Kaposi Sarcoma; Link; Liposomal Doxorubicin; Lymphoma; Lymphoproliferative Disorders; Malawi; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of prostate; Mentors; Molecular; North Carolina; Nucleotides; Paclitaxel; Pathogenesis; Pathology; Patients; Persons; Population; Positioning Attribute; Prognosis; Prognostic Factor; Prognostic Marker; Public Sector; Publications; Randomized Clinical Trials; Research; Research Personnel; Saliva; Shipping; Site; South Africa; Stains; Testing; Time; Trust; United States National Institutes of Health; Universities; Variant; Vincristine; Viral; Viral Load result; Work; base; biomarker performance; cohort; exceptional responders; exosome; experience; genome sequencing; innovation; low and middle-income countries; men; molecular marker; outcome prediction; response; response biomarker; screening; sex; standard of care; treatment guidelines; treatment response; whole genome

ABSTRACT: PROJECT 2. Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa This application seeks to establish the UNC-Malawi-South Africa Cancer Consortium (UMSACC). It responds to RFA-CA-20-001 and will establish a research center to develop capacity and conduct high-impact research focused on HIV-Associated Malignancy in U.S. and Low- and Middle-Income Country. Project 2 - Kaposi Sarcoma builds on longstanding collaborations between the University of North Carolina at Chapel Hill, Lighthouse Trust / Kamuzu Central Hospital in Malawi, and Stellenbosch University / Tygerberg Hospital in South Africa. This project has participation of investigators from all three countries: the US, Malawi and South Africa. UMSACC will establish and maintain core that support mentoring, administration, pathology and analyses jointly across three projects. Kaposi sarcoma is by far the most common cancer in people living in with HIV in Sub Saharan Africa and the US standard of care, liposomal doxorubicin, is not affordable or available in the public sector. Building on recent randomized clinical trials by the AIDS malignancy Consortium and the AIDS clinical trials group, we will document the experience with paclitaxel/ cART as new first line therapy in HIV-KS and seek to develop prognostic biomarkers of the disease, such as KSHV viral load, IL6, KSHV sequence variants and KSHV transcription.

摘要：项目2。与HIV相关的Kaposi肉瘤的临床和分子决定因素 马拉维和南非的当地护理疗法下的进展 该申请旨在建立UNC-Malawi-South非洲癌症联盟（UMSACC）。它回应 到RFA-CA-20-001，将建立一个研究中心来发展能力并进行高影响力研究 专注于 美国和低收入国家与艾滋病毒相关的恶性肿瘤。项目2 -Kaposi 肉瘤建立在北卡罗来纳大学教堂山分校之间的长期合作基础上 马拉维的Lighthouse Trust / Kamuzu Central Hospital和Stellenbosch University / Tygerberg医院 南非。该项目都有来自所有三个国家的调查人员的参与：美国，马拉维和南方 非洲。 UMSACC将建立和维护核心，以支持指导，管理，病理和 在三个项目中共同分析。卡波西肉瘤是迄今为止最常见的癌症 在撒哈拉以南非洲和美国护理标准的艾滋病毒中，脂质体阿霉素是不合适的，或者 可在公共部门提供。在艾滋病恶性财团最近进行的随机临床试验的基础上 和艾滋病临床试验小组，我们将以紫杉醇/购物车为新第一行的经验 HIV-K的治疗，并寻求发展该疾病的预后生物标志物，例如KSHV病毒负荷，IL6， KSHV序列变体和KSHV转录。